Therapure Announces Opening Of Custom Biologics Manufacturing Wing
Recently marked the official opening of Therapure Biopharma Inc.’s Custom Biologics Manufacturing Wing, which supports the development and manufacture of innovative medical treatments.
The facility’s advanced bioprotein production capabilities are attracting new clients from around the world. Therapure expects to create close to 100 jobs at the new facility and estimates that construction has already injected more than $17M into the local economy.
The facility expansion was made possible by funding support received from the Ontario government and Catalyst Fund, Limited Partnership II.
“Therapure is thrilled to officially celebrate the opening of its additional Custom Biologics Manufacturing Wing, which will enhance the company’s ability to be an international leader in biomanufacturing and meet the needs of a growing market”, said Nick Green, President and CEO of Therapure. “We are a proud member of Ontario’s life sciences community, and we look forward to contributing to growth and innovation in the region.”
“Ontario’s strategic investments are helping innovative companies compete in the global marketplace”, said Brad Duguid, Ontario Minister of Economic Development and Innovation. “Ontario’s support for Therapure has built upon our strengths in research and manufacturing to bring new, innovative medical treatments to patients while creating high quality jobs.”
“I am proud to see Therapure -- a Mississauga company-- reach this important company milestone today” said Hazel McCallion, Mayor of Mississauga. “Over the years, Therapure has grown in reputation to be a world-class leader in biopharmaceutical research, development and manufacturing. Today’s announcement highlights the company’s prospects for growth in Mississauga, and I look forward to witnessing the company’s continued success.”
About Therapure Biopharma Inc.:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins and biosimilars. As a contract development and manufacturing organization (CDMO), Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada-licensed 130,000 sq. ft. facility includes manufacturing, research and quality-control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMA, MHRA and Health Canada standards for the aseptic handling and purification of proteins. For more information, visit www.therapurebio.com.
SOURCE: Therapure Biopharma Inc.